Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 ‐Year Data from the Open‐Label BeyoND Study-Reference-Cited by-同舟云学术

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 ‐Year Data from the Open‐Label BeyoND Study

Published:2021-09-08 Issue:11 Volume:36 Page:2687-2692
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Movement Disorders

Author:

Poewe Werner¹,Stocchi Fabrizio²,Arkadir David³,Ebersbach Georg⁴,Ellenbogen Aaron L.⁵,Giladi Nir⁶,Isaacson Stuart H.⁷,Kieburtz Karl⁸,LeWitt Peter⁹,Olanow C. Warren⁸^ORCID,Simuni Tanya¹⁰,Thomas Astrid¹¹,Zlotogorski Abraham¹²,Adar Liat¹³,Case Ryan¹³^ORCID,Oren Sheila¹³,Fuchs Orenbach Shir¹³,Rosenfeld Olivia¹³,Sasson Nissim¹³,Yardeni Tami¹³,Espay Alberto J.¹⁴^ORCID,

Affiliation:

1. Department of Neurology Medical University Innsbruck Innsbruck Austria

2. University and Institute for Research and Medical Care IRCCS San Raffaele Rome Italy

3. Department of Neurology, The Faculty of Medicine, Hadassah Medical Center Hebrew University of Jerusalem Jerusalem Israel

4. Movement Disorder Clinic Beelitz‐Heilstaetten Beelitz Germany

5. Michigan Institute for Neurological Disorders Farmington Hills Michigan USA

6. Tel Aviv Medical Center, Sackler School of Medicine, Sagol School of Neurosciences Neurological Institute, Tel‐Aviv University Tel Aviv Israel

7. Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida USA

8. Departments of Neurology Wayne State University School of Medicine and Henry Ford Hospital Detroit Michigan USA

9. Clintrex Research Corp Sarasota Florida USA

10. Northwestern University Feinberg School of Medicine Chicago Illinois USA

11. Department of Neuroscience, Imaging and Clinical Sciences and Center of Advanced Studies and Technology CAST University Chieti Pescara Chieti Italy

12. Department of Dermatology, The Faculty of Medicine, Hadassah Medical Center Hebrew University of Jerusalem Jerusalem Israel

13. NeuroDerm Ltd Rehovot Israel

14. James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders University of Cincinnati Cincinnati Ohio USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.28758

Reference17 articles.

1. ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD [abstract];Giladi N;Mov Disord,2017

2. Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study

3. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

4. Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS)

5. Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease;The Lancet Neurology;2024-09

2. Clinicians’ viewpoints on current paradigms of care and research in Parkinson’s disease;Journal of Neural Transmission;2024-08-19

3. Subcutaneous Levodopa: A New Engine for the Vintage Molecule;Neurology and Therapy;2024-06-14

4. Levodopa infusion therapies for Parkinson disease;Current Opinion in Neurology;2024-05-23

5. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial;The Lancet Neurology;2024-05